Zoetis Inc. (NYSE:ZTS) Stock Holdings Increased by Freestone Capital Holdings LLC

Freestone Capital Holdings LLC lifted its stake in Zoetis Inc. (NYSE:ZTS) by 2.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 34,755 shares of the company’s stock after purchasing an additional 906 shares during the quarter. Freestone Capital Holdings LLC’s holdings in Zoetis were worth $5,663,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also made changes to their positions in the company. Callahan Advisors LLC lifted its position in shares of Zoetis by 90.4% in the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after purchasing an additional 6,221 shares in the last quarter. Pensionfund Sabic increased its holdings in Zoetis by 55.6% in the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after buying an additional 4,000 shares during the last quarter. CIBC Asset Management Inc increased its holdings in Zoetis by 24.1% in the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after buying an additional 46,050 shares during the last quarter. PFW Advisors LLC acquired a new position in Zoetis in the fourth quarter worth approximately $1,764,000. Finally, Alberta Investment Management Corp increased its holdings in Zoetis by 2,050.0% in the fourth quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock worth $4,904,000 after buying an additional 28,700 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ZTS. Leerink Partners began coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective on the stock. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. UBS Group began coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. Piper Sandler increased their price target on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Finally, Morgan Stanley lowered their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $215.90.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Zoetis Trading Down 1.7 %

Shares of Zoetis stock opened at $166.96 on Thursday. The company’s fifty day simple moving average is $166.57 and its 200-day simple moving average is $176.99. The company has a market cap of $74.76 billion, a price-to-earnings ratio of 30.52, a PEG ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.33.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, sell-side analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. Zoetis’s payout ratio is presently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.